Sandbox AQ, the Alphabet spin-out backed with $500 million in investment, in June 2023 unveiled it AQBioSim division. The division is working to bring SandoxAQ’s AI and quantum-inspired computing to develop new treatments for intractable medical conditions including neurodegenerative diseases and cancer. The company is working with leading drug developers and university medical centers to accelerate drug development, reduce costs, and improve the rate of clinical success. We spoke to Nadia Harhen, general manager of simulation and optimization for SandboxAQ, about the challenges of drug development it is seeking to address, how Sandbox AQ is leveraging quantum technologies, and why it is seeking to tackle an intractable set of diseases. One note: As we were preparing to publish this episode, Sandbox AQ announced it acquired Good Chemistry, a computational chemistry company that leverages AI, quantum, and other advanced technologies to accelerate drug discovery. The deal is expected to enhance SandboxAQ’s existing computational chemistry and simulation capabilities, adding talent, technologies, and industry insights.